Management of access to branded psychotropic medications in private health plans
Clinical TherapeuticsPublished 1 February 2007
Dominic Hodgkin, Constance M. Horgan, Deborah W. Garnick, Elizabeth L. Merrick, Joanna Volpe-Vartanian
Citations20
SJR quartileQ1
SJR score0.98
SNIP1.02
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Private plans were managing psychotropic costs using copayment incentives rather than administrative controls, which was less intrusive for clinicians, but resulting higher copayments could worsen already high rates of nonadherence; future research should examine this issue.
Abstract
Based on the results of this analysis,private plans were managing psychotropic costs using copayment incentives rather than administrative controls. This approach was less intrusive for clinicians, but resulting higher copayments could worsen already high rates of nonadherence; future research should examine this issue.
Keywords
MedicineEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
New England Journal of MedicineBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
1,049 Citations2006A. John Rush, Madhukar H. Trivedi +11 more
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.
The Journal of Clinical PsychiatryPredictors of Noncompliance in Patients With Schizophrenia
543 Citations2002Diana O. Perkins
By considering the factors leading to noncompliance and adopting a comprehensive strategy for improving compliance, encompassing psychosocial intervention and optimum choice of medication, the management of schizophrenia could be greatly improved.
PEDIATRICSOnce-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings
379 Citations2001William E. Pelham, Elizabeth M. Gnagy +16 more
New England Journal of MedicineThe Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending
336 Citations2003Haiden A. Huskamp, Patricia A. Deverka +4 more
Different changes in formulary administration may have dramatically different effects on utilization and spending and may in some instances lead enrollees to discontinue therapy.
JAMAThe End of Managed Care
253 Citations2001James C. Robinson
By default, if not by design, the consumer is emerging as the locus of priority setting in health care and the shift to consumerism is driven by a widespread skepticism of governmental, corporate, and professional dominance.
JAMAEmployer Drug Benefit Plans and Spending on Prescription Drugs
227 Citations2002Geoffrey Joyce
Adding an additional level of co-payment, increasing existing co-payments or coinsurance rates, and requiring mandatory generic substitution all reduced plan payments and overall drug spending among working-age enrollees with employer-provided drug coverage.
Archives of Internal MedicinePhysicians' Attitudes About Prescribing and Knowledge of the Costs of Common Medications
210 Citations2000Steven Reichert, Todd Simon +1 more
Physicians were predisposed to being cost-conscious in their prescribing habits, but lacked accurate knowledge about actual costs and insurance coverage of drugs.
PubMedThe design of the community tracking study: a longitudinal study of health system change and its effects on people.
209 Citations1996Peter Kemper, Daniel M. Blumenthal +9 more
The Design of the Community Tracking Study: A Longitudinal Study of Health System Change and Its Effects on People is the first in what I hope will be a series of occasional articles describing large-scale data collection efforts and plans for analyzing such data.
The Journal of Clinical PsychiatryFluoxetine Treatment of Patients With Major Depressive Disorder Who Failed Initial Treatment With Sertraline
204 Citations1997Michael E. Thase, Sharon L. Blomgren +3 more
Findings indicate that fluoxetine and sertraline, two widely used SSRIs, are not interchangeable and patients who either have had trouble tolerating or have not responded to sertRALine may do well on fluoxettine treatment.
Annals of PharmacotherapyDiscontinuing or Switching Selective Serotonin-Reuptake Inhibitors
187 Citations2002Scott Bull, Enid M. Hunkeler +5 more
Adverse effects are the most frequent reason for discontinuing or switching SSRIs within the first 3 months of treatment, and informing patients of potential adverse effects does not appear to prevent premature discontinuation, but may increase the patient's awareness and reporting of mild to moderate adverse effects.
Health AffairsPrescription Drugs And The Changing Patterns Of Treatment For Mental Disorders, 1996–2001
185 Citations2005Samuel H. Zuvekas
Examination of trends in mental health and substance abuse treatment between 1996 and 2001 finds that use of ambulatory services remained constant, but prescription drug use increased rapidly, with the result that 5.5 million more Americans received treatment in 2001.
PubMedImpact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
101 Citations2005Pamela B. Landsman, Winnie Yu +3 more
Use of retail prescription medications within 9 specific therapeutic classes decreased as copayments increased, and demand for pharmaceuticals was relatively inelastic with these copayment increases.
Milbank QuarterlyMental Health Policy and Psychotropic Drugs
84 Citations2005Richard G. Frank, Rena M. Conti +1 more
The policy issues related to psychotropic drugs with respect to their role in determining access to mental health treatment and the cost and quality of mental health care are outlined.
Health AffairsHealth Benefits In 2005: Premium Increases Slow Down, Coverage Continues To Erode
77 Citations2005Jon R. Gabel, Gary Claxton +6 more
Findings on the state of job-based health insurance in spring 2005 and how it has changed during recent years are reported.
Archives of General PsychiatryImpact of 3-Tier Formularies on Drug Treatment of Attention-Deficit/Hyperactivity Disorder in Children
71 Citations2005Haiden A. Huskamp, Patricia A. Deverka +5 more
The copayment increases associated with 3-tier formulary implementation by 1 employer resulted in lower total ADHD medication spending, sizeable increases in out-of-pocket expenditures for families of children with ADHD, and a significant decrease in the probability of using these medications.
Health AffairsManaging Psychotropic Drug Costs: Will Formularies Work?
63 Citations2003Haiden A. Huskamp
Health AffairsU.S. Spending For Mental Health And Substance Abuse Treatment, 1991–2001
56 Citations2005Tami L. Mark, Rosanna M. Coffey +4 more
During this period, Medicaid has increased to be the largest payer of mental health care, with prescription drugs the fastest-growing spending component.
PubMedChoice of maintenance medication for schizophrenia.
38 Citations2003John M. Davis, Nancy Chen
Research on the newer-generation antipsychotics, including ziprasidone, aripiprazole, and quetiapine, shows these agents to be efficacious and safe, although the limited amount of data on these agents precludes a definitive evaluation of their efficacy and safety.
Archives of Internal MedicineThree-Tiered–Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs
30 Citations2004Becky A. Briesacher, Sachin Kamal‐Bahl +3 more
Three-tier formularies appear to reduce the use of COX-2-selective inhibitors among all patients with arthritis, even those at risk of experiencing gastrointestinal complications from using nonselective NSAIDs.
Annals of Clinical PsychiatryMatching the Bipolar Patient and the Mood Stabilizer
23 Citations2003Alan J. Gelenberg, Ronald W. Pies
An analysis of predictors of medication response in bipolar disorder provides a basis for matching patients with optimal medication regimens and Randomized, controlled studies in bipolar populations are needed.
Annals of PharmacotherapyAre Incentive-Based Formularies Inversely Associated with Drug Utilization in Managed Care?
21 Citations2005Patrick P. Gleason, Brent W. Gunderson +1 more
Emerging data suggest a potential inverse relationship between pharmaceutical utilization and incentive-based formularies that increase member contribution to drug costs.
American Journal of OphthalmologyThe end of managed care. Robinson JC. JAMA 2001;285:2622–2628.
8 Citations2001Thomas J. Liesegang